BioStock: Interview with Professor Rolf Ljung, member of Idogen’s SAB
Idogen’s scientific advisory board consists of knowledgeable researchers and doctors active in Idogen’s fields of interest. One of them is Rolf Ljung, senior professor of paediatrics at Lund University, who has extensive knowledge regarding haemophilia. Professor Ljung will be involved with Idogen’s first clinical study with IDO 8 in patients with severe haemophilia A who have developed antibodies against their vital treatment with coagulation factor VIII. In an interview with BioStock, Rolf Ljung talks about the upcoming study and how Idogen’s treatment can counteract the problems
Expanded Project Scope
The deepened collaboration between Attana and Linnaeus University is well under way and project preparation has been completed including the installation of a new Attana system and recruitment and training of project personnel. Non-clinical diagnostic testing will commence in the coming weeks with preliminary results scheduled for release in Q2.
As previously communicated, the initial work will focus on assay optimization and benchmarking of the Attana SARS-CoV-2 immunoassay. However, in light of the most recent COVID research showing reduced vaccine efficacy
